Hexagon Nutrition shareholders approve FY26 dividend at 33rd AGM
- Hexagon Nutrition held its 33rd AGM on September 22, 2026, via video conferencing
- Shareholders approved the declaration of dividend for FY26
- Dr. Nikhil Arun Kelkar was re-appointed as Joint Managing Director
- Remuneration revisions were approved for the Chairman, MD, and JMD
- 42 members participated in the meeting, meeting quorum requirements

*this image is generated using AI for illustrative purposes only.
Hexagon Nutrition Limited held its 33rd Annual General Meeting on September 22, 2026, where shareholders approved key resolutions including the declaration of a dividend for FY26 and the reappointment of Dr. Nikhil Arun Kelkar as Joint Managing Director.
The meeting, conducted via video conferencing, commenced at 11:30 am and concluded at 12:22 pm. A total of 42 members participated through the virtual platform, satisfying the requisite quorum under the Companies Act, 2013. The proceedings were chaired by Arun Kelkar, Chairman and Executive Director.
Key resolutions passed
Shareholders voted on eleven agenda items, primarily focusing on financial approvals, director appointments, and remuneration revisions. The adoption of standalone and consolidated financial statements for FY26 was approved without qualifications from the statutory auditors.
The following significant resolutions were put to vote:
- Adoption of standalone and consolidated financial statements for FY26
- Declaration of dividend for FY26
- Re-appointment of Dr. Nikhil Arun Kelkar (DIN: 02302369) as Joint Managing Director retiring by rotation
- Appointment of Mr. Raghunath Sawant (DIN: 11863172) as Executive Director
- Revision in remuneration for Chairman Arun Purushottam Kelkar, Managing Director Vikram Arun Kelkar, and Joint Managing Director Nikhil Arun Kelkar
- Appointment of M/S. N. L. Bhatia & Associates as Secretarial Auditors
- Ratification of remuneration to cost auditors for FY27
- Alteration of articles of association regarding Malani Ventures Private Limited
- Re-appointment of Arun Purushottam Kelkar as Chairman and Director
Board attendance and governance
The Board demonstrated strong engagement with both physical and virtual participation. The Chairman, Managing Director, Joint Managing Director, and additional director attended physically, while three independent directors joined virtually. The Company Secretary confirmed that no qualifications were noted in the Statutory Auditors' Report on the financial statements.
| Role | Name | Attendance Mode |
|---|---|---|
| Chairman & Executive Director | Arun Kelkar | Physical |
| Managing Director | Vikram Kelkar | Physical |
| Joint Managing Director | Nikhil Kelkar | Physical |
| Additional Director | Raghunath Sawant | Physical |
| Independent Director | Nimesh Shukla | Physical |
| Independent Director | Meena Mehta | Physical |
| Chief Financial Officer | Soman Jana | Physical |
| Company Secretary | Vedanti Vartak | Physical |
| Independent Director | Aparna Sakpal | Virtual |
| Independent Director | Keval Shah | Virtual |
| Independent Director | Payal Gagliani | Virtual |
Voting and compliance
E-voting was facilitated through NSDL, with Rachana Shanbhag of D. A. Kamat & Co. serving as the scrutinizer. Members who did not vote via remote e-voting prior to the meeting were given a 15-minute window during the session to cast their votes electronically. The voting results and the scrutinizer's report will be submitted separately to the stock exchanges.
Historical Stock Returns for Hexagon Nutrition
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.94% | -4.29% | -7.32% | +44.60% | +44.60% | +44.60% |
How might the appointment of Mr. Raghunath Sawant as Executive Director influence Hexagon Nutrition's strategic direction in the nutraceutical sector?
What are the anticipated impacts of the revised remuneration structures for the Kelkar family leadership on shareholder sentiment and corporate governance ratings?
Given the clean statutory audit report, what specific growth metrics or market expansion plans did management highlight for FY27 during the Q&A session?

































